Statement: The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial, compared to cohort 2.
Primary_evidence: Outcome Measurement:    Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10   Overall survival (OS) was defined as the time from randomization to death due to any cause.   Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) Results 1:    Arm/Group Title: Pembrolizumab   Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years).   Overall Number of Participants Analyzed: 96   Median (95% Confidence Interval)   Unit of Measure: Months  12.7        (9.9 to 16.3) Results 2:    Arm/Group Title: Chemotherapy   Arm/Group Description: Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.   Overall Number of Participants Analyzed: 98   Median (95% Confidence Interval)   Unit of Measure: Months  11.6        (8.3 to 13.7)